Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulbactam pivoxil is the oral prodrug form of sulbactam, a semi-synthetic beta-lactamase inhibitor. After oral administration, the ester bond in sulbactam pivoxil is cleaved to release active sulbactam. Sulbactam acts as a suicide inhibitor of bacterial beta-lactamase enzymes by irreversibly binding to their active site, thereby preventing these enzymes from degrading co-administered beta-lactam antibiotics and improving their efficacy. Sulbactam itself has weak antibacterial activity through inhibition of penicillin-binding proteins (PBP) 1 and 3 but not PBP2. The primary clinical use is as an adjuvant with other beta-lactams for treating infections caused by beta-lactamase-producing bacteria[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulbactam pivoxil.